Navigation Links
Sequenom Announces Preliminary 2013 Operational Highlights And Objectives For 2014
Date:1/12/2014

ed persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Laboratories
Sequenom Laboratories, a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names SensiGene™, MaterniT21 PLUS™, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists and ophthalmologists. Sequenom Laboratories is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

SEQUENOM®, MaterniT21™ PLUS, SensiGene™, HerediT™, NextView™, RetnaGene™, IMPACT Dx™ and MassArray® are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statement
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's objectives for 2014 including primary financial and R&D objectives, expectations of continued reimbursement from large commercial payors, the Company's expectations to continue to lead the industry in expanding the use of and reimbursement for noninvasive prenatal testing (NIPT) and to work with payors to gain coverage for its tests, the Company's goals for 2014 and expectations to achieve those goals to continue to build value for shareholders and maintain its leadership position in NIPT, further review of financial results for the fiscal year and quarter ended December 31, 2013 to be conducte
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
3. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
4. Sequenom Announces Exercise In Full Of Over-Allotment Option And Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom Announces Participation At The Barclays Global Healthcare Conference
8. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - YOLO ... the manufacturing and distribution of medical and aesthetic ... market clearance for YOLO,s new generation body contouring ... has completed its second-generation low-level laser device for ... advancements to our patented technology while continuing to ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... notification from the Food and Drug Administration ("FDA" or the ... March 31, 2015, has been placed on clinical hold pending ... related to the stability of the drug substance and drug ... The Company had sought approval of their IND application ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3YOLO Medical Inc. receives FDA clearance for body contouring laser 2ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4
... HONG KONG, Sept. 20, 2011 /PRNewswire-Asia/ -- Golden ... subsidiaries collectively as the "Group," - 801.HK; 910801.TW), a ... of 2.0% interest in FunTalk China Holdings Limited, the ... the Group,s effective interest in FunTalk China will be ...
... NEW YORK, September 20, 2011 Preetha ... the United Nations Summit at New York held by ... of Non-Communicable Diseases. Non-communicable diseases, such as ... disease, account for more than 63 percent of all ...
Cached Medicine Technology:Golden Meditech Disposes of 2.0% Stake in FunTalk China for US$15 Million 2Preetha Reddy, Managing Director, Apollo Hospitals Invited to United Nations Summit on NCDs 2
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial Plastic ... non-surgical double-chin eliminator. Dr. Stong is double board ... to offer Kybella treatments . The FDA recently ... the chin, promising to safely dissolve fat deposits and ... sought immediate solutions for their double chin were forced ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... (ACE) has just released the first-ever congenital ... Congenital Cardiac Catheterization Laboratory (PCCL) accreditation. Driven ... CHD standards are a comprehensive review of ... with congenital heart disease. , “The ACE ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... tests separately predict the likelihood that a patient,s breast ... the cancer,s vulnerability to chemotherapy or hormone therapy, researchers ... Center report at the first American Society of Clinical ... Francisco. , Each predictor - of prognosis, of ...
... to headline Boston forums, BOSTON, Sept. 7 ... and former Republican,Governor Mike Huckabee (AR) will address ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) ... AARP,s annual,member event. The candidates will address AARP,s ...
... PA, Sept. 7 /PRNewswire-FirstCall/ - MDS Pharma,Services, a ... has won the Good Clinical Practice Journal (GCPj) ... access to new medicines. This,award is one of ... year to,recognize excellence in clinical research. MDS Pharma ...
... hours of instruction improved relationships with patients, study claims ... evidence suggests that a bit of theatrics can help ... on the experience of a small group of internal ... workshops and lectures led by university theater professors. , ...
... October 16, 2007, SUNNYVALE, Calif., Sept. 7 ... has set October 16, 2007, as the,date of the ... with a wholly owned subsidiary of Medtronic. The ... Time, at,Kyphon,s corporate headquarters located at 1221 Crossman Avenue, ...
... LifeQuest World,Corporation (formerly PhytoLabs Inc.) announced today that the ... contest to allow the,public to participate in choosing a ... 30, 2007. The company was unable to use any ... prize of a trip for two to,Las Vegas was ...
Cached Medicine News:Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 2Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 3Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 4Health News:Presidential Candidates Address Health, Financial Security at AARP's Life@50+ 2Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 2Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 3Health News:LifeQuest Announces End of Immunity Health Challenge Contest 2
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: